New Low T Warning Required By Food and Drug Administration

FDA Requires New Warning Label for Testosterone Drugs

The U.S. Food and Drug Administration has announced that testosterone products must now carry a warning label about the general risk of blood clots in the veins.  Blood clots in the veins may include conditions such as pulmonary embolism or deep vein thrombosis.  These are serious health conditions that can be fatal if a blood clot travels into the lungs.  The labeling change for low testosterone drugs is not the first time that the treatments have been in the spotlight for potential serious health conditions that could accompany their use.

There has been much discussion on the safety and potential side effects regarding testosterone prescribed to treat men with low testosterone or “low-t”. Studies have shown a link between serious adverse health events such as heart attacks, strokes and even death in some patients that have used testosterone replacement therapies.  A warning about the risk of blood clots relating to a condition known as polycythemia (an abnormal rise in the number of red blood cells) has already been in place for patients taking low t treatments.  This new warning requirement is not related to the previous warning for polycythemia or the FDA’s continuing investigation into the heart attacks, strokes and deaths that have been reported in some patients that took low t drugs.

The number of prescriptions written for low testosterone treatments has dramatically increased in the past several years and more and more men have taken these treatments to combat conditions such as low sex drive, weight gain and loss of energy.  Anyone considering low testosterone replacement therapies or already taking low t drugs should have a thorough conversation with their doctor about these potential risks.

Patients that have been harmed by taking low testosterone drugs may be entitled to financial compensation.  If you or someone that you know has been harmed by taking low testosterone drugs, please contact DeMayo Law Offices, L.L.P. for a free case evaluation.  DeMayo Law Offices can be reached toll free at (877) 333-1000 or via email at [email protected]

Office Locations

With North Carolina office locations in Charlotte, Hickory, Monroe and in Columbia, South Carolina, DeMayo Law Offices have been serving the state since 1992. You can contact us 24/7 and if you are unable to come to us - we will come to you.


Provide the below information and we will contact you.

  • This field is for validation purposes and should be left unchanged.
Phone icon
Call Us 24/7
Location icon
home icon
We Come
To You

Please do not include any confidential or sensitive information in this form. This form sends information by non-encrypted email which is not secure. Submitting this form does not create an attorney-client relationship.

Member of the Multi-Million Dollar Advocates Forum Member of the Million Dollar Advocates Forum Top 100 Trial Lawyers North Carolina Advocates for Justice
AV Preeminent Client Champion DeMayo Law Offices is a BBB Accredited Business Rated by Super Lawyers

Membership in the Million Dollar Advocates Forum is limited to attorneys who have won million and multi-million dollar verdicts and settlements. Criteria for membership in Million Dollar Advocates can be found by clicking here. DeMayo Law Offices, L.L.P. does not represent that similar results will be achieved in your case. Each case is different and must be evaluated separately.

The National Trial Lawyers is a national organization composed of the Top 100 Trial Lawyers from each state. Membership is obtained through special invitation and is extended only to those attorneys who exemplify superior qualifications, leadership, reputation, influence, stature, and profile as trial lawyers, both civil plaintiff and criminal defense. More information can be found at the National Trial Lawyers web site by clicking here. DeMayo Law Offices, L.L.P. does not represent that similar results will be achieved in your case. Each case is different and must be evaluated separately.